Multicenter Randomized control study of Immunoadsorption therapy (IAPP) for acute attacks relapsing-remitting Multiple Sclerosis

Multicenter Randomized control study of Immunoadsorption therapy (IAPP) for acute attacks relapsing-remitting Multiple Sclerosis - Japanese trial of Immunoadsorption therapy for acute attacks of relapsing-remitting Multiple Sclerosis (JIMS study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006153

Enrollment

Registered

2011-09-01

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

IAPP group :treated by Immunoadsorption theapy 5 times/2weeks HIMP control group :treated by steroid pulse therapy (1g/day), 3 3sessions/week during 2weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Relapsing-remitting Multiple Sclerosis patients fulfill the McDonald diagnostic criteria.

Exclusion criteria

Exclusion criteria: High-risk patients of hypovolemia with sever cardiovascular disease, brain disorder and autonomic disorder. MRI evidence of a contiguous spinal cord lesion 3 or more segments in length and/or anti-AQP4-IgG seronegativity.

Design outcomes

Primary

Measure	Time frame
Changing EDSS score at 3 weeks	—

Secondary

Measure	Time frame
EDSS score, FS grade QOL assessment MRI, Blood tests	—

Countries

Japan

Contacts

Public ContactLIN YOUWEI, MD.,

National Center of Neurology and Psychiatry National Center Hospital

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026